share_log

IFresh And CytRx Corporation Among The List Of The Most Active Winners And Losers Of Tuesday’s US Session

Via news ·  Apr 19, 2022 17:35

(VIANEWS) – Another day of trading has ended and here's today's list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are iFresh, Super Micro Computer, and CYREN Ltd..

RankFinancial AssetPriceChangeUpdated (EST)
1iFresh (IFMK)0.05719.67%2022-04-19 14:19:44
2Super Micro Computer (SMCI)44.5521.69%2022-04-19 14:47:33
3CYREN Ltd. (CYRN)2.7112.92%2022-04-18 19:06:06
4Escalon Medical Corp. (ESMC)0.1110%2022-04-19 04:17:06
5Plug Power (PLUG)28.079.84%2022-04-19 14:59:16
6Roku (ROKU)117.018.44%2022-04-19 14:51:50
7Celsius Holdings (CELH)57.207.82%2022-04-19 14:49:49
8GameStop (GME)152.277.64%2022-04-19 14:58:38
9StoneCo (STNE)11.107.45%2022-04-19 14:52:04
10Generac Holdlings (GNRC)267.467.3%2022-04-19 14:57:02

The three most active and biggest losers today are CytRx Corporation, Esperion Therapeutics, and Evolving Systems.

RankFinancial AssetPriceChangeUpdated (EST)
1CytRx Corporation (CYTR)0.13-28.89%2022-04-18 19:08:06
2Esperion Therapeutics (ESPR)5.03-14.6%2022-04-19 04:23:18
3Evolving Systems (EVOL)1.28-11.72%2022-04-19 05:07:12
4FalconStor Software (FALC)1.04-9.57%2022-04-19 05:23:15
5DURECT Corporation (DRRX)0.44-7.64%2022-04-18 21:14:06
6First Majestic Silver (AG)13.00-6.41%2022-04-19 14:55:47
7Fate Therapeutics (FATE)35.48-6.06%2022-04-19 07:07:07
8Epizyme (EPZM)0.72-6.03%2022-04-19 03:13:13
9TherapeuticsMD (TXMD)0.27-5.74%2022-04-19 14:52:30
10Enanta Pharmaceuticals (ENTA)70.50-5.05%2022-04-19 03:09:07

Most Active Winners today

1. iFresh (IFMK) – 719.67%

Through its subsidiaries, iFresh Inc. operates a network grocery store chains in the northern-eastern United States. The company operates in two segments: Wholesale and Retail. It offers vegetables, seafood and meats as well as snacks and seasonings. The company's brands include Feiyan and Green Acre as well as Redolent, Redolent and Golden Smell. It also sells products in wholesale shops, supermarkets and restaurants. It had nine supermarkets, two wholesale shops and one in-house business. It sells its products online and has a delivery network throughout suburban areas. Founded in 1995, iFresh Inc. is based in Long Island City (New York).

NASDAQ ended the session with iFresh rising 719.67% to $0.05 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.

Volume

Today's last reported volume for iFresh is 9902 which is 125.14% above its average volume of 4398.

iFresh's last close was $0.01, 99.64% under its 52-week high of $1.68.

iFresh's Revenue

Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 94.26M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

iFresh's stock is considered to be oversold (<=20).

iFresh's Stock Yearly Top and Bottom Value

iFresh's stock is valued at $0.05 at 17:32 EST, way below its 52-week high of $1.68 and way higher than its 52-week low of $0.00.

iFresh's Moving Average

iFresh's worth is way above its 50-day moving average of $0.02 and way below its 200-day moving average of $0.60.

More news about iFresh.

2. Super Micro Computer (SMCI) – 21.69%

Super Micro Computer, Inc., along with its affiliates, designs and produces high-performance storage and server solutions that are modular and open-architecture. The company's products include complete servers and storage as well as modular blade servers and blades. It also offers full racks and networking devices as well as server management software and sub-systems. Support and services are provided by the subsidiaries. The company also provides a range of application-optimized server solutions, including rackmount and blade servers, storage systems, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, and SuperDoctor 5. It also offers accessories and subsystems for server boards and chassis. The company also offers server system configuration and upgrade services. It also provides technical documentation. It also offers on-site and help desk support for server and storage system; as well as customer support, which includes ongoing maintenance and technical support. It sells its products to enterprises, cloud computing and artificial intelligence markets, as well as 5G and edge computing market. The company sells products via direct sales, distributors and value-added resellers. It operates primarily in America, Europe, Asia and abroad. Super Micro Computer, Inc., was established in 1993. Its headquarters are in San Jose, California.

NASDAQ ended the session with Super Micro Computer rising 21.69% to $44.55 on Tuesday, after five consecutive sessions in a row of gains. NASDAQ jumped 2.15% to $13,619.66, after two sequential sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Volume

Today's last reported volume for Super Micro Computer is 1454280 which is 500.34% above its average volume of 242242.

Super Micro Computer's last close was $36.61, 23.71% under its 52-week high of $47.99.

The company's growth estimates for the current quarter and the next is 23.8% and 50%, respectively.

Super Micro Computer's Revenue

Year-on-year quarterly revenue growth grew by 35.5%, now sitting on 3.83B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Super Micro Computer's stock is considered to be oversold (<=20).

Super Micro Computer's Stock Yearly Top and Bottom Value

Super Micro Computer's stock is valued at $44.55 at 17:32 EST, below its 52-week high of $47.99 and way above its 52-week low of $32.88.

Super Micro Computer's Moving Average

Super Micro Computer's value is way higher than its 50-day moving average of $40.04 and way above its 200-day moving average of $39.21.

More news about Super Micro Computer.

3. CYREN Ltd. (CYRN) – 12.92%

Cyren Ltd. and its subsidiaries develop and market information security solutions to protect Web, email and mobile transactions across the United States, Germany and other European countries. They also sell these products internationally. It offers software-as-a-service (SaaS) cybersecurity solutions that protect businesses, their employees, and customers from email, files, and the web threats. Cyren offers threat detection services. These include an email security engine with anti-spam outbound, IP reputation and virus outbreak detection; a malware detection engine to protect email apps; and a Web security engine to help customers provide URL classification to allow web browser filtering. Cyren also offers threat intelligence products such as real-time threat detection, threat hunting and threat hunting intelligence. Cyren Enterprise Email Security products are also offered by the company, such as Cyren Email Security (a cloud-based secure mail gateway), Cyren Inbox Security (an anti-phishing product for Microsoft 365) and Cyren Threat InDepth. This threat intelligence allows executives and security personnel to see evolving threats to their email systems and makes decisions about how to minimize them. The company sells products via direct and indirect channels. These include distributors and value-added resellers. It also offers managed services to enterprises and original equipment producers. The former name of the company was Commtouch Software Ltd., but it changed its name in January 2014 to Cyren Ltd. Cyren Ltd. was founded in 1991. It is located in Herzliya in Israel.

NASDAQ ended the session with CYREN Ltd. jumping 12.92% to $2.71 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.

Volume

Today's last reported volume for CYREN Ltd. is 3499560 which is 13.96% below its average volume of 4067550.

CYREN Ltd.'s last close was $2.71, 85.74% below its 52-week high of $19.00.

CYREN Ltd.'s Revenue

Year-on-year quarterly revenue growth declined by 12.8%, now sitting on 31.19M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

CYREN Ltd.'s stock is considered to be oversold (<=20).

CYREN Ltd.'s Stock Yearly Top and Bottom Value

CYREN Ltd.'s stock is valued at $2.71 at 17:32 EST, way below its 52-week high of $19.00 and way higher than its 52-week low of $1.98.

CYREN Ltd.'s Moving Average

CYREN Ltd.'s worth is way under its 50-day moving average of $4.91 and way under its 200-day moving average of $8.32.

More news about CYREN Ltd..

4. Escalon Medical Corp. (ESMC) – 10%

Escalon Medical Corp. designs, produces, markets and distributes pharmaceuticals and medical devices in the field of ophthalmology both in the United States as well internationally. A-Scan provides details about the inner structure of your eye. B-Scan is a diagnostic tool which gives information to doctors if the media inside the eye become opaque or cloudy. UBM provides high-frequency/high-resolution ultrasound information that provides precise information about the anterior section of your eye. Pachymeter measures the cornea's thickness. It also sells intraocular gases products such as SF6 and C3F8 that are used in vitreoretinal surgery as a temporary tamponade during detached retina surgery. The company manufactures and distributes a patented universal gas delivery kit, which delivers gas directly from the canister. It also offers disposable surgical bags that can be used for vitreoretinal surgeries; as well as AXIS Image Management System, which allows you to manage images via the Web browser using any device, regardless of manufacturer or modality. Independent sales reps and a network distributors sell the company's products to hospitals. Internal sales staff also help with sales. Escalon Medical Corp. is located in Wayne, Pennsylvania.

NASDAQ ended the session with Escalon Medical Corp. rising 10% to $0.11 on Tuesday, after two successive sessions in a row of gains. NASDAQ jumped 2.15% to $13,619.66, after two consecutive sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Volume

Today's last reported volume for Escalon Medical Corp. is 11267 which is 10.6% below its average volume of 12603.

Escalon Medical Corp.'s last close was $0.11, 75% below its 52-week high of $0.44.

Escalon Medical Corp.'s Revenue

Year-on-year quarterly revenue growth declined by 6.8%, now sitting on 10.54M for the twelve trailing months.

Escalon Medical Corp.'s Stock Yearly Top and Bottom Value

Escalon Medical Corp.'s stock is valued at $0.11 at 17:32 EST, way under its 52-week high of $0.44 and way higher than its 52-week low of $0.08.

Escalon Medical Corp.'s Moving Average

Escalon Medical Corp.'s worth is below its 50-day moving average of $0.11 and way under its 200-day moving average of $0.15.

More news about Escalon Medical Corp..

5. Plug Power (PLUG) – 9.84%

Plug Power Inc. offers turnkey hydrogen fuel cell solutions to the stationary and electric mobility markets of North America and Europe. The company specializes in proton exchange membrane fuel cells and fuel processing technologies. It also offers fuel cell/battery hybrid technology and hydrogen storage and dispensing infrastructure. GenDrive is a hydrogen-fueled, PEM fuelcell system for electric vehicle material handling; GenFuel provides hydrogen fueling generation, storage and dispensing systems; GenCare provides ongoing support and maintenance programs for GenDrive fuel cells and GenSure products; GenSure provides stationary fuel cell solutions that provide modular PEM fuel cell power that can be used to meet the grid-support and backup power needs of the utility, transportation and telecommunication sectors. GenKey is a complete solution to transition to fuel cell power. ProGen is a fuel stack and engine technology that can be used in stationary and mobile fuel cells systems as well as in electric delivery vans. It sells its products through direct sales, OEM manufacturers and dealer networks. Plug Power Inc. was established in 1997 in Latham (New York).

NASDAQ ended the session with Plug Power jumping 9.84% to $28.07 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for Plug Power is 42288100 which is 100.03% above its average volume of 21140800.

Plug Power's last close was $25.55, 45.05% below its 52-week high of $46.50.

News about Plug Power today

  • Plug Power stock surges after liquid green hydrogen delivery agreement with Walmart. According to today's article on MarketWatch, "Shares of Plug Power Inc. surged 4.4% in premarket trading Tuesday, after the alternative energy company disclosed an agreement with Walmart Inc. for an option to deliver up to 20 tons per day of liquid green hydrogen. ", "Walmart has been an early adopter of innovative hydrogen and fuel cell technology for over a decade, and our hydrogen-powered solutions offer a tool to enhance productivity improvements for Walmart's operations," said Plug Power Chief Executive Andy Marsh. "
  • Plug Power shares rise after inking hydrogen delivery deal with Walmart. According to today's article on MarketWatch, "Shares of Plug Power Inc. surged 4.4% in premarket trading Tuesday, after the alternative energy company disclosed an agreement with Walmart Inc. for an option to deliver up to 20 tons per day of liquid green hydrogen. ", "Walmart has been an early adopter of innovative hydrogen and fuel cell technology for over a decade, and our hydrogen-powered solutions offer a tool to enhance productivity improvements for Walmart's operations," said Plug Power Chief Executive Andy Marsh. "

Plug Power's Sales

Plug Power's sales growth is 65% for the present quarter and 108.4% for the next. The company's growth estimates for the current quarter and the next is 91.1% and 25%, respectively.

Plug Power's Revenue

Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 31.34M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Plug Power's stock is considered to be overbought (>=80).

Plug Power's Stock Yearly Top and Bottom Value

Plug Power's stock is valued at $28.07 at 17:32 EST, way under its 52-week high of $46.50 and way above its 52-week low of $17.51.

Plug Power's Moving Average

Plug Power's value is way higher than its 50-day moving average of $24.60 and under its 200-day moving average of $28.57.

More news about Plug Power.

6. Roku (ROKU) – 8.44%

Roku, Inc., along with its affiliates, operate a streaming TV platform. It operates under two distinct segments: Platform and Player. The company's platform allows people to search for and find different TV shows and movies, live music and news. The company has 36.9million active accounts as of December 31, 2019. The company also offers advertising products such as videos ads, brand sponsorships and audience development campaigns. It manufactures and licenses TVs and subscription billing services. The company also offers accessories and streaming media players under the Roku name. It sells brand-name channel buttons for remote controls. The company sells its products through distributors and retailers as well as direct to its customers via its website. It has offices in several countries, including the United States, Canada and Mexico. It was established in Los Gatos in California in 2002.

NASDAQ ended the session with Roku jumping 8.44% to $117.01 on Tuesday, after five sequential sessions in a row of losses. NASDAQ rose 2.15% to $13,619.66, after two successive sessions in a row of losses, on what was an all-around positive trend trading session today.

Volume

Today's last reported volume for Roku is 5732150 which is 22.99% below its average volume of 7443500.

Roku's last close was $107.91, 78.01% below its 52-week high of $490.76.

Roku's Sales

Roku's sales growth is 84.7% for the current quarter and 46.7% for the next. The company's growth estimates for the current quarter and the next is a negative 33.3% and a negative 61.2%, respectively.

Roku's Revenue

Year-on-year quarterly revenue growth grew by 79%, now sitting on 2.03B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Roku's stock is considered to be overbought (>=80).

Roku's Stock Yearly Top and Bottom Value

Roku's stock is valued at $117.01 at 17:32 EST, way below its 52-week low of $196.94.

Roku's Moving Average

Roku's worth is way under its 50-day moving average of $280.17 and way below its 200-day moving average of $341.49.

More news about Roku.

7. Celsius Holdings (CELH) – 7.82%

Celsius Holdings, Inc. markets, distributes, sells and promotes functional, calorie-burning, fitness drinks in the United States as well as internationally. It offers a variety of beverages, such as carbonated orange and wild berry, cola and grape, kiwi guava and watermelon. Celsius Heat is a nutritional supplement that contains carbonated flavorings such as orange jack'd and blueberry pomegranate. Blueberry pomegranate. strawberry dragonfruit. tangerine grapefruit. It distributes products via direct-store distribution distributors as well as retailers that include supermarkets and convenience stores as well as drug and nutritional stores and mass merchants. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings jumping 7.82% to $57.20 on Tuesday, after two successive sessions in a row of losses. NASDAQ rose 2.15% to $13,619.66, after two successive sessions in a row of losses, on what was an all-around up trend trading session today.

Volume

Today's last reported volume for Celsius Holdings is 545244 which is 42.07% below its average volume of 941345.

Celsius Holdings's last close was $53.05, 51.87% below its 52-week high of $110.22.

Celsius Holdings's Sales

Celsius Holdings's sales growth is 151.4% for the ongoing quarter and 108.3% for the next. The company's growth estimates for the present quarter and the next is 100% and 400%, respectively.

Celsius Holdings's Revenue

Year-on-year quarterly revenue growth grew by 157.6%, now sitting on 245.68M for the twelve trailing months.

Celsius Holdings's Stock Yearly Top and Bottom Value

Celsius Holdings's stock is valued at $57.20 at 17:32 EST, way below its 52-week high of $110.22 and way above its 52-week low of $39.45.

Celsius Holdings's Moving Average

Celsius Holdings's worth is above its 50-day moving average of $54.72 and way under its 200-day moving average of $71.06.

More news about Celsius Holdings.

8. GameStop (GME) – 7.64%

GameStop Corp. is a retailer of multi-channel consumer electronics and video games in America, Canada, Australia and Europe. It sells pre-owned and new video games platforms, accessories including controllers and virtual reality headsets as well as new and preowned software. The company also offers collectibles that include licensed merchandise. These products are primarily related to video games, TV, and film industries. It operates stores and ecommerce websites under the Micromania, GameStop and EB Games brands. The Zing Pop Culture brand also offers collectibles and Game Informer. This publication, which is both digital and print, features reviews, tips and information about the video gaming industry. The company had 5,509 shops in 14 countries as of February 1, 2020. GSC Holdings Corp. used to be the company's name. GameStop Corp. was established in 1996 in Grapevine Texas.

NYSE ended the session with GameStop rising 7.64% to $152.27 on Tuesday, after two consecutive sessions in a row of losses. NYSE jumped 1.17% to $16,658.90, after two successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Volume

Today's last reported volume for GameStop is 2244120 which is 52.29% below its average volume of 4704230.

GameStop's last close was $92.69, 73.11% under its 52-week high of $344.66.

News about GameStop today

  • GME stock price: gamestop corp sinks as markets pull back to start the week. According to today's article on FXStreet, "It seems the stock split announcement for GameStop has lost its luster for investors. ", "There has been some notable insider buying as recently as the end of March for GameStop shares. "

The company's growth estimates for the present quarter is a negative 41.8% and positive 11.1% for the next.

GameStop's Revenue

Year-on-year quarterly revenue growth grew by 29.1%, now sitting on 5.88B for the twelve trailing months.

GameStop's Stock Yearly Top and Bottom Value

GameStop's stock is valued at $152.27 at 17:32 EST, way below its 52-week high of $344.66 and way higher than its 52-week low of $77.58.

GameStop's Moving Average

GameStop's value is way above its 50-day moving average of $122.43 and below its 200-day moving average of $162.30.

More news about GameStop.

9. StoneCo (STNE) – 7.45%

StoneCo Ltd. offers financial technology solutions for clients and integrate partners. It allows customers to transact electronically in Brazil through in-store and online channels. StoneCo Ltd. distributes their solutions through its proprietary Stone Hubs. These hubs offer local sales and services, and technology and solutions for digital merchants via sales personnel, technical vendors and sales staff. It also sells brick-and mortar and digital merchants with the help of a sales team. As of December 31, 2019, the company served approximately 495,100 clients primarily small-and-medium-sized businesses; and 116 integrated partners, such as global payment service providers, digital marketplaces, and integrated software vendors. It was established in 2012 in George Town in the Cayman Islands.

NASDAQ ended the session with StoneCo rising 7.45% to $11.10 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for StoneCo is 8596570 which is 2.93% below its average volume of 8856130.

StoneCo's last close was $10.33, 89.14% under its 52-week high of $95.12.

StoneCo's Sales

StoneCo's sales growth is 40.1% for the current quarter and 51.4% for the next.

StoneCo's Revenue

Year-on-year quarterly revenue growth grew by 21.7%, now sitting on 3.33B for the twelve trailing months.

StoneCo's Stock Yearly Top and Bottom Value

StoneCo's stock is valued at $11.10 at 17:32 EST, way below its 52-week low of $14.02.

StoneCo's Moving Average

StoneCo's value is way below its 50-day moving average of $27.87 and way below its 200-day moving average of $52.11.

More news about StoneCo.

10. Generac Holdlings (GNRC) – 7.3%

Generac Holdings Inc. manufactures and sells power generator equipment and energy storage systems. It also designs and produces other products that are suitable for residential, light commercial, industrial, and institutional markets. It offers engine, alternators and transfer switches as well as other components that are fueled by natural gas and liquid propane. The company also offers residential automatic standby generators, with an output range of 6kW-60kW. It also has liquid-cooled generators that have outputs between 22kW and 150kW. Mobile Link is a remote monitoring device for home generators. And industrial diesel generators up to 3250kW. The company also offers portable generators with outputs from 800W up to 17.5kW, engine-driven power washers and water pumps, as well as outdoor power equipment such lawn mowers, trimmers, leaf and log splitters and chipper shredders. Clean energy solutions are available under both the PWRcell or PWRview brand. It also offers light towers and mobile generators as well as flameless heaters. Light-commercial standby generators with outputs of 22kW to 150kW, along with related transfer switches, provide three-phase power to small and medium-sized businesses. Industrial generators have an output range from 10kW to 3250kW, which can be used for emergency back-up in healthcare, telecom, datacom and commercial offices. The company also sells accessories and after-market parts to dealers. Distributed products are sold through independent dealers and industrial distributors as well as national and regional retail partners. Generac Holdings Inc. is located in Waukesha in Wisconsin. It was established in 1959.

NYSE ended the session with Generac Holdlings rising 7.3% to $267.46 on Tuesday, after five consecutive sessions in a row of losses. NYSE rose 1.17% to $16,658.90, after two successive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Volume

Today's last reported volume for Generac Holdlings is 845867 which is 1.76% above its average volume of 831157.

Generac Holdlings's last close was $249.27, 52.46% below its 52-week high of $524.31.

Generac Holdlings's Sales

Generac Holdlings's sales growth is 37.2% for the present quarter and 35.3% for the next. The company's growth estimates for the ongoing quarter and the next is 14.9% and 39.2%, respectively.

Generac Holdlings's Revenue

Year-on-year quarterly revenue growth grew by 69.7%, now sitting on 2.82B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Generac Holdlings's stock is considered to be overbought (>=80).

Generac Holdlings's Stock Yearly Top and Bottom Value

Generac Holdlings's stock is valued at $267.46 at 17:32 EST, way below its 52-week high of $524.31 and way higher than its 52-week low of $213.50.

Generac Holdlings's Moving Average

Generac Holdlings's value is way below its 50-day moving average of $433.60 and way below its 200-day moving average of $389.04.

More news about Generac Holdlings.

Most Active Losers Today

1. CytRx Corporation (CYTR) – -28.89%

CytRx Corporation is a biopharmaceutical development and research company that focuses on rare and oncology. The company is involved in research and clinical development for novel anticancer drugs. It uses novel linker technology to increase the amount and release of anticancer agents at tumors. Its leading candidates are linker activated drugs release (LADR-7, 8 and 9 respectively, as well as Aldoxorubicin which is a conjugate for the prescribed cytotoxin, doxorubicin. This drug binds to circulating blood albumin and concentrates the drug directly at the tumor site. ACDx is an albumin companion diagnostic tool that identifies patients most likely to be benefited from these potential drug candidates. CytRx Corporation, which was founded in 1985 is located in Los Angeles.

NASDAQ ended the session with CytRx Corporation falling 28.89% to $0.13 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for CytRx Corporation is 364002 which is 317.89% above its average volume of 87103.

CytRx Corporation's last close was $0.13, 97.28% below its 52-week high of $4.70.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

CytRx Corporation's stock is considered to be overbought (>=80).

CytRx Corporation's Stock Yearly Top and Bottom Value

CytRx Corporation's stock is valued at $0.13 at 17:32 EST, way below its 52-week high of $4.70 and above its 52-week low of $0.13.

CytRx Corporation's Moving Average

CytRx Corporation's worth is way under its 50-day moving average of $0.39 and way below its 200-day moving average of $0.57.

More news about CytRx Corporation.

2. Esperion Therapeutics (ESPR) – -14.6%

Esperion Therapeutics, Inc. is a pharmaceutical company that develops and markets medicines to treat patients suffering from high levels of low-density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. Daiichi Sankyo Europe GmbH and Serometrix have entered into a collaboration and license agreement. This allows the company to in-license their oral small-molecule PCSK9 inhibitor programs. Esperion Therapeutics, Inc., was founded in 2008. It is located in Ann Arbor, Michigan.

NASDAQ ended the session with Esperion Therapeutics sliding 14.6% to $5.03 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for Esperion Therapeutics is 2759780 which is 116.33% above its average volume of 1275710.

Esperion Therapeutics's last close was $5.03, 82.52% below its 52-week high of $28.78.

Esperion Therapeutics's Sales

Esperion Therapeutics's sales growth is 49.1% for the present quarter and 122.6% for the next. The company's growth estimates for the ongoing quarter and the next is 31.9% and 66.9%, respectively.

Esperion Therapeutics's Revenue

Year-on-year quarterly revenue growth grew by 275.9%, now sitting on 72.68M for the twelve trailing months.

Esperion Therapeutics's Stock Yearly Top and Bottom Value

Esperion Therapeutics's stock is valued at $5.03 at 17:33 EST, way under its 52-week high of $28.78 and way above its 52-week low of $3.28.

Esperion Therapeutics's Moving Average

Esperion Therapeutics's value is higher than its 50-day moving average of $4.63 and way below its 200-day moving average of $8.75.

More news about Esperion Therapeutics.

3. Evolving Systems (EVOL) – -11.72%

Evolving Systems, Inc. offers real-time digital engagement services and solutions to both the mobile carrier market and the consumer financial markets internationally. It offers activation and acquisition solutions. These include Smart Dealer which enables SIM card retailers to sell SIM cards. Dynamic SIM Allocation is a SIM/eSIM activation tool. The company's activation and acquisition solutions include Tertio Service activation, which is used to activate new subscribers or add new services to existing subscribers; and Number Inventory and Management Solution. This solution automates the management of operators' telephone numbers and other communications identifiers. The company also offers value management and customer analytics solutions such as the Profiling Engine (a rules-driven flexible aggregater that supports dynamic and static profiling of subscribers); Campaign Engine which is used for delivering marketing offers and campaigns to subscribers; Campaign Workflow, Journey Manager and Campaign Workflow, which offer predefined templates to support specific digital marketing strategies; Real-time Predictions and Machine Learning Module, which allows revenue, usage and churn predictions. It also offers a Social Media Integration Solution that allows carriers to increase their engagement with subscribers. The company also offers loyalty and customer retention solutions to reduce churn and increase customer lifetimes. The company also offers managed IT and marketing services, as well as customer value management and solutions. It was established in Englewood in Colorado in 1985.

NASDAQ ended the session with Evolving Systems falling 11.72% to $1.28 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for Evolving Systems is 362059 which is 266.28% above its average volume of 98847.

Evolving Systems's last close was $1.28, 59.49% below its 52-week high of $3.16.

Evolving Systems's Revenue

Year-on-year quarterly revenue growth grew by 3%, now sitting on 27.39M for the twelve trailing months.

Evolving Systems's Stock Yearly Top and Bottom Value

Evolving Systems's stock is valued at $1.28 at 17:33 EST, way under its 52-week high of $3.16 and higher than its 52-week low of $1.27.

Evolving Systems's Moving Average

Evolving Systems's worth is way under its 50-day moving average of $1.83 and way under its 200-day moving average of $2.17.

More news about Evolving Systems.

4. FalconStor Software (FALC) – -9.57%

FalconStor Software, Inc., is a storage software firm that develops, sells, and supports data migration, business continuity, disaster relief, optimized backup, duplication, and any other maintenance, implementation, or engineering services. FalconStor Virtual Tape Library is a program that replaces legacy tape libraries. It also offers FalconStor Continuous data Protector, which allows for instant recovery, data availability and reliability, as well as FalconStor Storage Server, for virtualizing data and ensuring business continuity across heterogeneous environments. FalconStor RecoverTrac Disaster Recovery Technology streamlines implementation, testing and execution of disaster recovery procedures. FalconStor MicroScanTM Technology reduces data transfer during replication, by eliminating inefficiencies and errors at the file system and application layer. It sells products via authorized partners, value-added distributors and solution providers. FalconStor Software, Inc., was founded in 1994. It is located in Austin, Texas.

NASDAQ ended the session with FalconStor Software dropping 9.57% to $1.04 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for FalconStor Software is 326 which is 89.61% below its average volume of 3139.

FalconStor Software's last close was $1.04, 82.67% below its 52-week high of $6.00.

FalconStor Software's Revenue

Year-on-year quarterly revenue growth declined by 26%, now sitting on 14.02M for the twelve trailing months.

FalconStor Software's Stock Yearly Top and Bottom Value

FalconStor Software's stock is valued at $1.04 at 17:33 EST, way below its 52-week high of $6.00 and way higher than its 52-week low of $0.55.

FalconStor Software's Moving Average

FalconStor Software's worth is way under its 50-day moving average of $1.67 and way under its 200-day moving average of $2.87.

More news about FalconStor Software.

5. DURECT Corporation (DRRX) – -7.64%

DURECT Corporation is a biopharmaceutical firm that develops drugs based on the company's epigenetic regulators and pharmaceutical programs. ALZET is a product line of ALZET osmotic pumps, accessories, and equipment that are used in research on mice, rats and other laboratory animals. DUR-928 is an orally bioavailable, endogenous small molecule. It has completed Phase Ib clinical trials to treat nonalcoholic steatohepatitis patients. The company also offers POSIMIR which is a pain relief product that delivers bupivacaine for up to 7 days in adults. The company markets its ALZET products through direct sales in the United States as well as via a network distributors in Japan and Europe. It has agreements and strategic collaboration with Indivior UK Ltd., Virginia Commonwealth University Intellectual Property Foundation, Santen Pharmaceutical Co., Ltd., Sandoz AG, and Gilead Sciences, Inc. DURECT Corporation was established in 1998. The corporation is located in Cupertino, California.

NASDAQ ended the session with DURECT Corporation sliding 7.64% to $0.44 on Tuesday, following the last session's downward trend. NASDAQ rose 2.15% to $13,619.66, after two successive sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Volume

Today's last reported volume for DURECT Corporation is 1091780 which is 66.5% above its average volume of 655713.

DURECT Corporation's last close was $0.44, 77.2% below its 52-week high of $1.93.

DURECT Corporation's Sales

DURECT Corporation's sales growth is a negative 21.9% for the ongoing quarter and 10.7% for the next.

DURECT Corporation's Revenue

Year-on-year quarterly revenue growth grew by 230.6%, now sitting on 13.98M for the twelve trailing months.

DURECT Corporation's Stock Yearly Top and Bottom Value

DURECT Corporation's stock is valued at $0.44 at 17:33 EST, below its 52-week low of $0.44.

DURECT Corporation's Moving Average

DURECT Corporation's value is way under its 50-day moving average of $0.62 and way under its 200-day moving average of $1.02.

More news about DURECT Corporation.

6. First Majestic Silver (AG) – -6.41%

First Majestic Silver Corp. is engaged in exploration, development and production of mineral properties, with a particular focus on Mexico. San Dimas Silver/Gold Mine is 100% owned by the company. It consists of 119 concessions that cover an area 71,868 ha in Durango. Santa Elena Silver/Gold Mine covers an area 57,656 Ha in Sonora. La Encantada Silver Mine has 22 concessions and an area 4,076 ha in Coahuila. Surface land ownership totals 1,343 He. The company also has an interest in the Springpole gold-silver project that covers approximately 41,943 ha in Ontario, Canada. The original name of the company was First Majestic Resource Corp., but it changed its name in November 2006 to First Majestic Silver Corp. First Majestic Silver Corp. is an American corporation that was founded in 1979. Its headquarters are located in Vancouver, Canada.

NYSE ended the session with First Majestic Silver sliding 6.41% to $13.00 on Tuesday while NYSE rose 1.17% to $16,658.90.

Volume

Today's last reported volume for First Majestic Silver is 8102550 which is 30.99% above its average volume of 6185230.

First Majestic Silver's last close was $13.39, 29.27% below its 52-week high of $18.93.

First Majestic Silver's Revenue

Year-on-year quarterly revenue growth declined by 1%, now sitting on 496.32M for the twelve trailing months.

First Majestic Silver's Stock Yearly Top and Bottom Value

First Majestic Silver's stock is valued at $13.00 at 17:33 EST, way under its 52-week high of $18.93 and way above its 52-week low of $9.29.

First Majestic Silver's Moving Average

First Majestic Silver's worth is higher than its 50-day moving average of $11.97 and higher than its 200-day moving average of $12.40.

More news about First Majestic Silver.

7. Fate Therapeutics (FATE) – -6.06%

Fate Therapeutics, Inc. is a biopharmaceutical firm in clinical stage. It develops programmed cell immunotherapies for immune disorders and cancer. It is currently developing NK-and T-cell immuno-oncology programmes for AML, B-cell Lymphoma, and advanced Solid Tumors. FT516 to treat AML, B-cell and multiple myeloma. FT538 to manage multiple myeloma. FT576 and FT538 are for multiple myeloma. FT819 and solid cancers. FT536 and FT500 to deal with advanced solid tumours. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc., was founded in 2007. It is located in San Diego, California.

NASDAQ ended the session with Fate Therapeutics falling 6.06% to $35.48 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.

Volume

Today's last reported volume for Fate Therapeutics is 790201 which is 40.28% below its average volume of 1323370.

Fate Therapeutics's last close was $35.48, 63.58% under its 52-week high of $97.43.

Fate Therapeutics's Sales

Fate Therapeutics's sales growth is a negative 16% for the ongoing quarter and 62.8% for the next. The company's growth estimates for the present quarter and the next is a negative 58.3% and a negative 37.9%, respectively.

Fate Therapeutics's Revenue

Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 55.85M for the twelve trailing months.

Fate Therapeutics's Stock Yearly Top and Bottom Value

Fate Therapeutics's stock is valued at $35.48 at 17:33 EST, way under its 52-week high of $97.43 and way above its 52-week low of $29.40.

Fate Therapeutics's Moving Average

Fate Therapeutics's value is under its 50-day moving average of $36.56 and way under its 200-day moving average of $56.91.

More news about Fate Therapeutics.

8. Epizyme (EPZM) – -6.03%

Epizyme, Inc., is a biopharmaceutical firm in commercial stage. It develops, commercializes, and markets novel epigenetic drugs for cancer patients and other diseases throughout the United States. Tazemetostat is available for treatment of epithelioid tumors in adults or children. Tazemetostat is also developed in conjunction with Rituximab for patients with follicular Lymphoma. It also offers R-CHOP in front line patients with high-risk diffuse large B cell lymphoma (DLBCL) and PARP inhibitor to patients with solid platinum-resistant tumors such as small-cell lung carcinoma, triple-negative breast and ovarian cancer. It also develops Tazemetostat for patients with castration resistant prostate cancer and children and adults with INI1 negative tumors. The company also develops pinometostat to treat acute myeloid and acute lymphoblastic lesions; PRMT5 inhibitors for solid tumors patients; and PRMT1 inhibitor. Epizyme, Inc. is a partner of Genentech Inc., Glaxo Group Limited, Roche Molecular Systems, Inc., Lymphoma Academic Resource Organization, Eisai Co. Ltd., and HUTCHMED China Limited. It was founded in 2007, and has its headquarters in Cambridge, Massachusetts.

NASDAQ ended the session with Epizyme falling 6.03% to $0.72 on Tuesday while NASDAQ rose 2.15% to $13,619.66.

Volume

Today's last reported volume for Epizyme is 1917660 which is 40.86% below its average volume of 3242790.

Epizyme's last close was $0.72, 92.7% under its 52-week high of $9.86.

Epizyme's Sales

Epizyme's sales growth is a negative 1.4% for the current quarter and a decline by 3.4% for the next. The company's growth estimates for the present quarter and the next is 16.9% and 24.6%, respectively.

Epizyme's Revenue

Year-on-year quarterly revenue growth grew by 38.3%, now sitting on 37.43M for the twelve trailing months.

Epizyme's Stock Yearly Top and Bottom Value

Epizyme's stock is valued at $0.72 at 17:33 EST, way below its 52-week high of $9.86 and higher than its 52-week low of $0.70.

Epizyme's Moving Average

Epizyme's worth is way below its 50-day moving average of $1.33 and way below its 200-day moving average of $3.72.

More news about Epizyme.

9. TherapeuticsMD (TXMD) – -5.74%

TherapeuticsMD, Inc. is a United States women's health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company's clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD falling 5.74% to $0.27 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.

Volume

Today's last reported volume for TherapeuticsMD is 5149540 which is 26.89% below its average volume of 7043920.

TherapeuticsMD's last close was $0.28, 89.67% under its 52-week high of $2.75.

TherapeuticsMD's Sales

TherapeuticsMD's sales growth is 33.7% for the ongoing quarter and 29.3% for the next. The company's growth estimates for the present quarter and the next is 16.7% and 40%, respectively.

TherapeuticsMD's Revenue

Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD's stock is considered to be overbought (>=80).

TherapeuticsMD's Stock Yearly Top and Bottom Value

TherapeuticsMD's stock is valued at $0.27 at 17:34 EST, way below its 52-week low of $0.37.

TherapeuticsMD's Moving Average

TherapeuticsMD's value is way below its 50-day moving average of $0.66 and way under its 200-day moving average of $1.00.

More news about TherapeuticsMD.

10. Enanta Pharmaceuticals (ENTA) – -5.05%

Enanta Pharmaceuticals, Inc. is a biotechnology firm that develops small-molecule drugs to treat viral infections. The company's main research and development diseases targets are respiratory syncytial, non-alcoholic, steatohepatitis and SARS-CoV-2. It also has human metapneumovirus and hepatitis B viruses. Glecaprevir is available for chronic hepatitis C, and HCV. It's also offered under MAVYRET or MAVIRET. Enanta Pharmaceuticals, Inc. and Abbott Laboratories have a collaboration development and licensing agreement to develop and commercialize HCV NS3 inhibitor compounds and NS3/4A protease inhibitor compounds. This includes paritaprevir, glecaprevir, and glecaprevir in the treatment of chronic hepatitis C. Watertown, Massachusetts is the headquarters of Enanta Pharmaceuticals Inc. It was established in 1995.

NASDAQ ended the session with Enanta Pharmaceuticals sliding 5.05% to $70.50 on Tuesday, after two successive sessions in a row of losses. NASDAQ jumped 2.15% to $13,619.66, after two consecutive sessions in a row of losses, on what was an all-around bullish trend trading session today.

Volume

Today's last reported volume for Enanta Pharmaceuticals is 185820 which is 14.44% below its average volume of 217201.

Enanta Pharmaceuticals's last close was $70.50, 30.88% under its 52-week high of $102.00.

The company's growth estimates for the current quarter and the next is a negative 31.2% and a negative 21.8%, respectively.

Enanta Pharmaceuticals's Revenue

Year-on-year quarterly revenue growth declined by 12.9%, now sitting on 92.98M for the twelve trailing months.

Enanta Pharmaceuticals's Stock Yearly Top and Bottom Value

Enanta Pharmaceuticals's stock is valued at $70.50 at 17:34 EST, way under its 52-week high of $102.00 and way higher than its 52-week low of $40.37.

Enanta Pharmaceuticals's Moving Average

Enanta Pharmaceuticals's value is higher than its 50-day moving average of $68.12 and higher than its 200-day moving average of $64.95.

More news about Enanta Pharmaceuticals.

Stay up to date with our winners and losers daily report

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment